Arrow Therapeutics Selects A Further Hepatitis C Clinical Candidate

... Arrow Therapeutics, the London based antiviral drug discovery and development company, has announced that a further Hepatitis C compound, A-689, has entered full preclinical development. A-689 is the second compound from Arrow's broad approach to the NS5a target to enter development. November 2006 saw Arrow's first Hepatitis C compound, A-831, enter Phase I trials. [click link for full article] ...